

## List of Tables

Sr. No	Title	Page No.
<b>Chapter 1</b>		
Table 1.1	Polymorphism and gene expression studies of vitiligo patients from Gujarat population.	9
Table 1.2	VTCN1 protein expression in autoimmune diseases	26
Table 1.3	sVTCN1 levels in different autoimmune diseases	27
Table 1.4	VTCN1 in therapeutics of different autoimmune diseases	28
<b>Chapter 2</b>		
Table 2.1	Demographic characteristics of vitiligo patients and unaffected controls for genotyping study	49
Table 2.2	Primer details used for polymorphism analysis along with amplicon size and RE	50
Table 2.3	Demographic characteristics of vitiligo patients and unaffected controls of Gujarat recruited for skin biopsy (Gene expression study)	52
Table 2.4	Primer details used for gene expression analysis	52
Table 2.5	Demographic characteristics of vitiligo patients and unaffected controls of Gujarat recruited for skin biopsy (Protein expression studies)	53
Table 2.6	Distribution of genotypes and alleles for <i>VTCN1</i> rs12046117 (C/T) and rs10923223 (T/C) in vitiligo patients and controls	55
Table 2.7	Association of <i>VTCN1</i> rs12046117 (C/T) and rs10923223 (T/C) polymorphism with generalized and localized Vitiligo	56
Table 2.8	Association of <i>VTCN1</i> rs12046117 (C/T) and rs10923223 (T/C) polymorphism with active and stable Vitiligo	57
Table 2.9	Distribution of haplotype frequencies for <i>VTCN1</i> rs12046117 (C/T) and rs10923223 (T/C) polymorphisms in vitiligo patients and controls	58
Table 2.10	<i>In silico</i> analysis results for <i>VTCN1</i> rs12046117 and rs10923223 polymorphisms	58
<b>Chapter 3</b>		
Table 3.1	Demographic characteristics of vitiligo patients and unaffected controls for immunophenotyping from blood	78
Table 3.2	List of antibodies used in immunophenotypic analysis	79
Table 3.3	Demographic characteristics of vitiligo patients and unaffected controls for immunophenotyping from skin	80
Table 3.4	Immunophenotyping studies in vitiligo	93